Brokerages Anticipate OpGen, Inc. (OPGN) to Announce -$0.06 Earnings Per Share

Analysts expect OpGen, Inc. (NASDAQ:OPGN) to report ($0.06) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for OpGen’s earnings. OpGen posted earnings of ($0.21) per share during the same quarter last year, which suggests a positive year over year growth rate of 71.4%. The firm is expected to report its next quarterly earnings results on Thursday, March 22nd.

On average, analysts expect that OpGen will report full-year earnings of ($0.41) per share for the current year. For the next financial year, analysts anticipate that the firm will report earnings of ($0.15) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover OpGen.

A number of research analysts recently issued reports on OPGN shares. HC Wainwright set a $1.00 price objective on OpGen and gave the stock a “buy” rating in a report on Tuesday, July 18th. Zacks Investment Research upgraded OpGen from a “hold” rating to a “buy” rating and set a $0.25 price objective for the company in a report on Tuesday, August 15th.

A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. increased its position in shares of OpGen, Inc. (NASDAQ:OPGN) by 1.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 342,860 shares of the medical research company’s stock after buying an additional 5,500 shares during the quarter. Vanguard Group Inc. owned 1.25% of OpGen worth $219,000 as of its most recent SEC filing. Institutional investors and hedge funds own 10.90% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Brokerages Anticipate OpGen, Inc. (OPGN) to Announce -$0.06 Earnings Per Share” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at

OpGen (OPGN) traded down $0.01 during trading hours on Friday, hitting $0.26. The company had a trading volume of 1,245,100 shares, compared to its average volume of 1,136,195. The company has a quick ratio of 0.19, a current ratio of 1.23 and a debt-to-equity ratio of 0.03. OpGen has a fifty-two week low of $0.21 and a fifty-two week high of $3.10.

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with's FREE daily email newsletter.

Leave a Reply